Citigroup Inc. Takes Position in NeuroPace, Inc. (NASDAQ:NPCE)

Citigroup Inc. bought a new stake in shares of NeuroPace, Inc. (NASDAQ:NPCEFree Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,984 shares of the company’s stock, valued at approximately $29,000.

Several other large investors also recently added to or reduced their stakes in the company. State Street Corp lifted its stake in shares of NeuroPace by 2.1% in the first quarter. State Street Corp now owns 98,717 shares of the company’s stock valued at $810,000 after buying an additional 2,042 shares during the period. Renaissance Technologies LLC increased its holdings in shares of NeuroPace by 19.3% in the second quarter. Renaissance Technologies LLC now owns 17,300 shares of the company’s stock valued at $78,000 after purchasing an additional 2,800 shares in the last quarter. BlackRock Inc. increased its holdings in shares of NeuroPace by 11.2% in the second quarter. BlackRock Inc. now owns 36,117 shares of the company’s stock valued at $162,000 after purchasing an additional 3,646 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of NeuroPace by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 71,515 shares of the company’s stock valued at $106,000 after purchasing an additional 5,945 shares in the last quarter. Finally, Barclays PLC increased its holdings in shares of NeuroPace by 9,085.6% in the third quarter. Barclays PLC now owns 10,839 shares of the company’s stock valued at $105,000 after purchasing an additional 10,721 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at NeuroPace

In other NeuroPace news, insider Martha Morrell sold 1,923 shares of the business’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.08, for a total value of $28,998.84. Following the completion of the sale, the insider now owns 96,014 shares of the company’s stock, valued at approximately $1,447,891.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 27.50% of the company’s stock.

NeuroPace Stock Down 6.5 %

Shares of NPCE stock opened at $12.79 on Wednesday. The firm has a market capitalization of $336.12 million, a P/E ratio of -9.99 and a beta of 2.09. The firm’s fifty day moving average price is $14.83 and its two-hundred day moving average price is $10.92. NeuroPace, Inc. has a 1 year low of $3.80 and a 1 year high of $18.15. The company has a current ratio of 5.71, a quick ratio of 5.02 and a debt-to-equity ratio of 2.76.

NeuroPace (NASDAQ:NPCEGet Free Report) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.10. The company had revenue of $18.01 million for the quarter, compared to analyst estimates of $17.74 million. NeuroPace had a negative net margin of 50.38% and a negative return on equity of 153.76%. On average, equities analysts predict that NeuroPace, Inc. will post -1.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on NPCE shares. Lake Street Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of NeuroPace in a research note on Wednesday, December 27th. Cantor Fitzgerald raised their price objective on shares of NeuroPace from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Wells Fargo & Company raised shares of NeuroPace from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $16.00 to $20.00 in a research note on Thursday, March 14th. SVB Leerink assumed coverage on shares of NeuroPace in a research report on Tuesday, January 30th. They set an “outperform” rating and a $22.00 price target on the stock. Finally, Leerink Partnrs reissued an “outperform” rating on shares of NeuroPace in a research report on Tuesday, January 30th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.67.

View Our Latest Research Report on NeuroPace

NeuroPace Profile

(Free Report)

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

See Also

Want to see what other hedge funds are holding NPCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeuroPace, Inc. (NASDAQ:NPCEFree Report).

Institutional Ownership by Quarter for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.